NE-ADME 2024 Agenda
*Speakers and titles are subject to change. Updated 02/31/2024
*TIME SLOTS LISTED BELOW ARE EDT!!!
Thursday, June 13 2024 |
|||
Talk Title |
Speaker |
Company |
Time EDT |
Registration |
7:30 - 8:30 |
||
Conference Opening |
8:30 - 8:40 |
||
SESSION I: Complex Models to Support Drug Development Chairs: Mitesh Patel, Novartis & Ruchia Duggal, Merck |
|||
Session I Opening Remarks |
8:40 - 8:45 |
||
Plenary Lecture: BBB organoids (spheroids) for drug delivery to the brain + PET imaging - Title TBA | Choi-Fong Cho | Brigham and Women's Hospital, Harvard Medical School |
8:45 - 9:25 |
Organotypic Slice Cultures as a Model System to Understand Lipid Nanoparticle Delivery |
Hema Muralidharan |
Moderna |
9:25 - 9:55 |
Liver MPS Model Comparison for Clearance IVIVC |
Birk Poller |
Novartis, Basel |
9:55 - 10:25 |
Overcoming limitations of Caco-2 cells for ADME using adult human crypt-derived planar intestinal epithelium cultures | Ben Scruggs | Altis Biosystems | 10:25 - 10:55 |
Break |
10:55 - 11:15 |
||
Plenary Speaker Introduction | Vinayak Hosagrahara | Nimbus Therapeutics | 11:15 - 11:20 |
Plenary Lecture: ADMET In The Age of AI | Daniel Price | Nimbus Therapeutics |
11:20 - 12:00 |
Fatty Liver Disease Modeling In a Micropatterned Primary Hepatocyte Co-culture (HEPATOPAC): Applications In Drug Development & Screening | Karissa Cottier |
12:00 - 12:25 |
|
Lunch |
12:25 - 1:35 |
||
Vendor Talk | TBD |
1:35 - 1:45 |
|
SESSION II: PK/PD for New Modalities Chairs: Steven Louie, Moderna & Dallas Bednarczyk, Novartis |
|||
Session II Opening Remarks |
1:45 - 1:50 |
||
Use of PK/PD Modeling to Understand the Potential and Pitfalls of New Modalities- Picking the Winners from the Losers | Alison Betts | Takeda |
1:50 - 2:20 |
PK/PD models for glue degraders for BBB, CNS target - Title TBA | TK Phung | Novartis |
2:20 - 2:50 |
LNP's - Title TBA | Christopher Rowbottom | Moderna |
2:50- 3:20 |
Break |
3:20 - 3:40 |
||
SESSION III: Advanced Tools to Support Drug Discovery & Development Chairs: Joseph Tillotson, Pfizer & Seema Chauhan Kumar, Pioneering Medicines |
|||
Session III Opening Remarks |
3:40 - 3:45 |
||
Measurement of Target Exposure and Binding with Positron Emission Tomography (PET) Imaging in Drug Research and Development | Laigao Chen | Pfizer |
3:45 - 4:15 |
Title TBA | Jonathan Jackson | Pfizer |
4:15 - 4:45 |
Closing Remarks |
4:45- 4:50 |
||
Reception |
4:50- 5:50 |